(HealthDay News) — The American Society of Clinical Oncology (ASCO) has endorsed the European Association of Urology (EAU) guideline on muscle-invasive (MIBC) and metastatic bladder cancer, according to a special article published online March 21 in the Journal of Clinical Oncology.
Matthew I. Milowsky, M.D., from the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill, and colleagues reviewed the EAU guideline on MIBC and metastatic bladder cancer for developmental rigor. The ASCO Endorsement Panel reviewed the content and recommendations and found that the recommendations were clear, thorough, and based on the most relevant scientific evidence.
According to the recommendations, multidisciplinary care is critical for patients with MIBC and metastatic bladder cancer. Neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy is the standard treatment for MIBC; radical cystectomy alone is recommended for cisplatin-ineligible patients. In appropriately selected patients with MIBC and for some for whom cystectomy is not an option, chemoradiotherapy may be offered as an alternative to cystectomy. Cisplatin-containing combination chemotherapy or with carboplatin combination chemotherapy should be used for treatment of metastatic disease; single agents are recommended for patients ineligible for cisplatin.
“ASCO endorses all but one of the recommendations in the EAU guideline on MIBC and metastatic bladder cancer, by Witjes et al in 2015, with minor qualifying statements,” the authors write.
Several authors disclosed financial ties to the pharmaceutical and health care industries.